Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLIT2 can induce BC cell motility and chemotaxis, but the latter requires the presence of heparin.
|
30842157 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
(3) The interval from diagnosis of breast cancer to brain metastasis and brain metastasis to death were both much shorter in patients with low expression of Slit2 or Robo1 compared with the high expression group.
|
26400100 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway.
|
22898079 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SLIT2 gene is a novel tumor suppressor gene, whose hypermethylation has been detected in several malignances, including breast cancer, colorectal carcinoma and gliomas.
|
21627385 |
2011 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an effort to understand the molecular signature of BC in the Saudi population, we undertook this study to profile the methylation events in a series of key genes including Ras association (RalGDS/AF-6) domain family member 1 isoform a (RASSF1A), hypermethylated in cancer 1 (HIC1), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoic acid receptor beta (RARB2), estrogen receptor 1 (ESR1), progesterone receptor (PGR), paired-like homeodomain 2 (PITX2), secreted frizzled-related protein 1 (SFRP1), myogenic differentiation 1 (MYOD1), and slit homolog 2 (SLIT2), using MethyLight analysis in archival tumour samples.
|
21868547 |
2011 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this study was to investigate the prevalence of Slit2 promoter hypermethylation in both the tumor and serum samples of breast cancer patients with ductal carcinoma in situ (DCIS) or invasive breast carcinoma (IBC).
|
21894562 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, analysis of large breast tumor data sets revealed that Slit2 correlated positively with overall and recurrence-free survival, providing clinical validation for the tumor suppressor function for Slit2 in human breast cancer.
|
21148069 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLIT2 encodes an extracellular glycoprotein that can suppress breast cancer by regulating beta-catenin.
|
20068157 |
2010 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, both SLIT2 and SLIT3 are frequently methylated in gliomas and colorectal cancers, but the frequency of SLIT3 methylation in lung and breast cancer is significantly less than that for SLIT2.
|
15534609 |
2004 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SLIT2 promoter methylation was detected in 59% of breast cancer, 77% of non-small cell lung cancer, and 55% of small cell lung cancer cell lines.
|
12384551 |
2002 |